A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity
•We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Muc...
Saved in:
Published in | Oral oncology Vol. 136; p. 106190 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Mucoepidermoid carcinoma of the parotid gland, anti-PD-1 immunotherapy could be considered to further improve therapeutic qualities and prognosis.•Our case showed an encouraging efficacy of Capecitabine plus sintilimab combination therapy. This promising avenue deserves further study to apply this combination regimen to clinical practice. |
---|---|
AbstractList | •We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity treated with Capecitabine plus sintilimab and response evaluation was partial response (PR).•For MSI-H high grade Mucoepidermoid carcinoma of the parotid gland, anti-PD-1 immunotherapy could be considered to further improve therapeutic qualities and prognosis.•Our case showed an encouraging efficacy of Capecitabine plus sintilimab combination therapy. This promising avenue deserves further study to apply this combination regimen to clinical practice. |
ArticleNumber | 106190 |
Author | Lin, Zhiren Chen, Dongsheng Li, Yijie Xiao, Mingzhe Yuan, Feng Chai, Huizi Pan, Yanling |
Author_xml | – sequence: 1 givenname: Yanling surname: Pan fullname: Pan, Yanling email: 1037444804@qq.com organization: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570100, China – sequence: 2 givenname: Yijie surname: Li fullname: Li, Yijie email: 371148412@qq.com organization: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570100, China – sequence: 3 givenname: Feng surname: Yuan fullname: Yuan, Feng email: yuanfeng@csco.ac.cn organization: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570100, China – sequence: 4 givenname: Zhiren surname: Lin fullname: Lin, Zhiren email: abc697000@163.com organization: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570100, China – sequence: 5 givenname: Huizi surname: Chai fullname: Chai, Huizi email: huizi.chai@simceredx.com organization: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing 210002, China – sequence: 6 givenname: Mingzhe surname: Xiao fullname: Xiao, Mingzhe email: mingzhe.xiao@simceredx.com organization: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing 210002, China – sequence: 7 givenname: Dongsheng surname: Chen fullname: Chen, Dongsheng email: dongsheng.chen@simceredx.com organization: The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing 210002, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36463699$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkd1uFSEUhYmpsT_6CoZ45c0cYf7xrmnVNmnjhb0nDOw5s08HGIGpOY_lG8rxVOOlCQmE9e29NqxzcuK8A0LecbbhjLcfdhsf1Oyd9rPf7jclK8sstFywF-SM950oWCOqk3yu2r7oq645Jecx7hhjDW_YK3JatXVbtUKckZ-XNIBV4VENM1A9o0Ot5nwXF-8i0OQpWru6rE2gHxePLlF0Ew6YfIjUj_T-221xQyfcTnQblAF6v2oPCxoI1qOhWgWNzlt1gNMEdFHBpyxsZ-UM_YFponadEy55AgtJxbwgZpfftBqMt-jyUFo9Ydq_Ji9HNUd487xfkIfPnx6uboq7r19ury7vCl31LBWlaMaBa9b1bVU3ooaOcaGEblRVq64ejak1AC-FGLpRDD3Xghsjqm4cO17X1QV5f2y7BP99hZikxahhzjODX6Msu7pjrGxFk9GPR1QHH2OAUS4B85_uJWfykJjcyX8Tk4fE5DGxXPz22WcdLJi_pX8iysD1EYD82CeEIKNGcBoMBtBJGo__4_MLdXe0YA |
CitedBy_id | crossref_primary_10_1007_s40278_023_36712_6 |
Cites_doi | 10.1097/PAS.0000000000001252 10.5858/arpa.2016-0259-SA 10.1016/j.oraloncology.2018.04.001 10.1200/JCO.19.02105 10.1038/ng1083 10.1002/hed.26735 10.1016/S1470-2045(10)70245-X 10.1177/107327480901600103 10.1200/JCO.19.02107 |
ContentType | Journal Article |
Copyright | 2022 Elsevier Ltd |
Copyright_xml | – notice: 2022 Elsevier Ltd |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.oraloncology.2022.106190 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Dentistry |
EISSN | 1879-0593 |
EndPage | 106190 |
ExternalDocumentID | 10_1016_j_oraloncology_2022_106190 36463699 S1368837522004791 |
Genre | Letter Correspondence |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29N 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 71M 8P~ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAWTL AAXUO ABBQC ABFNM ABJNI ABLJU ABLVK ABMAC ABMZM ABOCM ABXDB ABYKQ ACDAQ ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B LCYCR M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K X7M XPP Z5R ZA5 ZGI ~G- AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c380t-295fb1c078634594e7019a9c5a34a74fdd4cee1299b7f9b81c91dd937ff71443 |
IEDL.DBID | AIKHN |
ISSN | 1368-8375 |
IngestDate | Fri Aug 16 10:43:25 EDT 2024 Thu Sep 26 17:24:57 EDT 2024 Sat Sep 28 08:20:22 EDT 2024 Fri Feb 23 02:39:57 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c380t-295fb1c078634594e7019a9c5a34a74fdd4cee1299b7f9b81c91dd937ff71443 |
Notes | SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 |
PMID | 36463699 |
PQID | 2747002695 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | proquest_miscellaneous_2747002695 crossref_primary_10_1016_j_oraloncology_2022_106190 pubmed_primary_36463699 elsevier_sciencedirect_doi_10_1016_j_oraloncology_2022_106190 |
PublicationCentury | 2000 |
PublicationDate | January 2023 2023-01-00 20230101 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – month: 01 year: 2023 text: January 2023 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Oral oncology |
PublicationTitleAlternate | Oral Oncol |
PublicationYear | 2023 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Tardy, Di Mauro, Ebran, Refae, Bozec, Benezery (b0055) 2018; 80 Li, Luo, Huang, Luo, Zhu (b0015) 2020; 20 Griffith, Schmitt, Little, Magliocca (b0025) 2017; 141 Tonon, Modi, Wu, Kubo, Coxon, Komiya (b0030) 2003; 33 Cipriani, Lusardi, McElherne, Pearson, Olivas, Fitzpatrick (b0035) 2019; 43 Laurie, Ho, Fury, Sherman, Pfister (b0020) 2011; 12 Meyer, Broaddus, Lu (b0040) 2009; 16 Chan, Van Abel, Lewis, Routman, Garcia, Karp (b0010) 2021; 43 Peraza, Gómez, Beltran, Amarista (b0005) 2020; 121 Le, Kim, Van Cutsem, Geva, Jäger, Hara (b0045) 2020; 38 Marabelle, Le, Ascierto, Di Giacomo, De Jesus-Acosta, Delord (b0050) 2020; 38 Tonon (10.1016/j.oraloncology.2022.106190_b0030) 2003; 33 Tardy (10.1016/j.oraloncology.2022.106190_b0055) 2018; 80 Peraza (10.1016/j.oraloncology.2022.106190_b0005) 2020; 121 Le (10.1016/j.oraloncology.2022.106190_b0045) 2020; 38 Meyer (10.1016/j.oraloncology.2022.106190_b0040) 2009; 16 Li (10.1016/j.oraloncology.2022.106190_b0015) 2020; 20 Cipriani (10.1016/j.oraloncology.2022.106190_b0035) 2019; 43 Marabelle (10.1016/j.oraloncology.2022.106190_b0050) 2020; 38 Griffith (10.1016/j.oraloncology.2022.106190_b0025) 2017; 141 Chan (10.1016/j.oraloncology.2022.106190_b0010) 2021; 43 Laurie (10.1016/j.oraloncology.2022.106190_b0020) 2011; 12 |
References_xml | – volume: 121 start-page: 713 year: 2020 end-page: 720 ident: b0005 article-title: Mucoepidermoid carcinoma. An update and review of the literature publication-title: J Stomatol Oral Maxi contributor: fullname: Amarista – volume: 43 start-page: 885 year: 2019 end-page: 897 ident: b0035 article-title: Mucoepidermoid carcinoma publication-title: Am J Surg Pathol contributor: fullname: Fitzpatrick – volume: 141 start-page: 381 year: 2017 end-page: 395 ident: b0025 article-title: New developments in salivary gland pathology: Clinically useful ancillary testing and new potentially targetable molecular alterations publication-title: Arch Pathol Lab Med contributor: fullname: Magliocca – volume: 43 start-page: 2663 year: 2021 end-page: 2671 ident: b0010 article-title: Mucoepidermoid carcinoma of the parotid gland: twenty-year experience in treatment and outcomes publication-title: Head Neck contributor: fullname: Karp – volume: 33 start-page: 208 year: 2003 end-page: 213 ident: b0030 article-title: T(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway publication-title: Nat Genet contributor: fullname: Komiya – volume: 16 start-page: 14 year: 2009 end-page: 22 ident: b0040 article-title: Endometrial cancer and lynch syndrome: clinical and pathologic considerations publication-title: Cancer Control contributor: fullname: Lu – volume: 80 start-page: 104 year: 2018 end-page: 107 ident: b0055 article-title: Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma publication-title: Oral Oncol contributor: fullname: Benezery – volume: 20 start-page: 1 year: 2020 end-page: 13 ident: b0015 article-title: Microsatellite instability: a review of what the oncologist should know publication-title: Cancer Cell Int contributor: fullname: Zhu – volume: 12 start-page: 815 year: 2011 end-page: 824 ident: b0020 article-title: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review publication-title: Lancet Oncol contributor: fullname: Pfister – volume: 38 start-page: 11 year: 2020 end-page: 19 ident: b0045 article-title: Phase II Open-Label study of pembrolizumab in Treatment-Refractory, microsatellite instability-High/Mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164 publication-title: J Clin Oncol contributor: fullname: Hara – volume: 38 start-page: 1 year: 2020 end-page: 10 ident: b0050 article-title: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/Mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study publication-title: J Clin Oncol contributor: fullname: Delord – volume: 43 start-page: 885 issue: 7 year: 2019 ident: 10.1016/j.oraloncology.2022.106190_b0035 article-title: Mucoepidermoid carcinoma publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000001252 contributor: fullname: Cipriani – volume: 141 start-page: 381 issue: 3 year: 2017 ident: 10.1016/j.oraloncology.2022.106190_b0025 article-title: New developments in salivary gland pathology: Clinically useful ancillary testing and new potentially targetable molecular alterations publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2016-0259-SA contributor: fullname: Griffith – volume: 121 start-page: 713 issue: 6 year: 2020 ident: 10.1016/j.oraloncology.2022.106190_b0005 article-title: Mucoepidermoid carcinoma. An update and review of the literature publication-title: J Stomatol Oral Maxi contributor: fullname: Peraza – volume: 80 start-page: 104 year: 2018 ident: 10.1016/j.oraloncology.2022.106190_b0055 article-title: Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2018.04.001 contributor: fullname: Tardy – volume: 38 start-page: 1 issue: 1 year: 2020 ident: 10.1016/j.oraloncology.2022.106190_b0050 article-title: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/Mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study publication-title: J Clin Oncol doi: 10.1200/JCO.19.02105 contributor: fullname: Marabelle – volume: 33 start-page: 208 issue: 2 year: 2003 ident: 10.1016/j.oraloncology.2022.106190_b0030 article-title: T(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway publication-title: Nat Genet doi: 10.1038/ng1083 contributor: fullname: Tonon – volume: 43 start-page: 2663 issue: 9 year: 2021 ident: 10.1016/j.oraloncology.2022.106190_b0010 article-title: Mucoepidermoid carcinoma of the parotid gland: twenty-year experience in treatment and outcomes publication-title: Head Neck doi: 10.1002/hed.26735 contributor: fullname: Chan – volume: 12 start-page: 815 issue: 8 year: 2011 ident: 10.1016/j.oraloncology.2022.106190_b0020 article-title: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70245-X contributor: fullname: Laurie – volume: 20 start-page: 1 issue: 1 year: 2020 ident: 10.1016/j.oraloncology.2022.106190_b0015 article-title: Microsatellite instability: a review of what the oncologist should know publication-title: Cancer Cell Int contributor: fullname: Li – volume: 16 start-page: 14 issue: 1 year: 2009 ident: 10.1016/j.oraloncology.2022.106190_b0040 article-title: Endometrial cancer and lynch syndrome: clinical and pathologic considerations publication-title: Cancer Control doi: 10.1177/107327480901600103 contributor: fullname: Meyer – volume: 38 start-page: 11 issue: 1 year: 2020 ident: 10.1016/j.oraloncology.2022.106190_b0045 article-title: Phase II Open-Label study of pembrolizumab in Treatment-Refractory, microsatellite instability-High/Mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164 publication-title: J Clin Oncol doi: 10.1200/JCO.19.02107 contributor: fullname: Le |
SSID | ssj0005150 |
Score | 2.4176583 |
Snippet | •We first to report a 64-year-old woman of Mucoepidermoid carcinoma of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 106190 |
SubjectTerms | Abdominal Cavity - pathology Carcinoma, Mucoepidermoid - pathology Humans Immune Checkpoint Inhibitors Parotid Gland - pathology Parotid Neoplasms - pathology |
Title | A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity |
URI | https://dx.doi.org/10.1016/j.oraloncology.2022.106190 https://www.ncbi.nlm.nih.gov/pubmed/36463699 https://search.proquest.com/docview/2747002695 |
Volume | 136 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELbKVgIuqJTXAq2MxNXdPJzEPnBYlVZb0PbSIvUW2fGEhmrjVTZ76KX_iX_ITB48JCohodz8iK2M4_nGnpmPsfcQaesgswJ1kRIyLCOhXaCECVVqI3wU0I3u8jxdfJGfrpKrHXY8xsKQW-Ww9_d7erdbDyWz4WvO1lU1uwjjVKF5hQCiy5OOJtAuqiMpJ2x3fvZ5cf7L0yNM-mDhVAnqMOYe7dy8KA7e112G6Fs0F6PoiIwk2qL_rqfuw6GdPjrdY08GIMnn_Vyfsh2o99mjj-T8Q_xt--zhcrg2f8a-z3kDK9PcUJwUH4MhsazzjwXeel5RnAjWXUNxs_ZV3fKqvq5sRWQ83Jd8eXEmFpySG_OvjXHAl9vCA9HLNitfOV4QJ1HtV4YaI6jka9P4Fis6jhBOx718dF7kK2gNotINbHCUrrWxznf0YvgiYrN4zi5PTy6PF2LgahBFrIJWRDopbVgg4EhjmWgJlObd6CIxsTSZLJ2TqI4RXGibldqqsNChc4iNyjJDmcUv2KT2NbxiPIwKaZ0qiT1HQhCrFKICbBI4CEqZRVMWj4LJ131Gjnx0VfuW_y7OnMSZ9-Kcsg-jDPM_1leOquOf-r8bBZ_jD0i3KqYGv93kZNaTJauTKXvZr4if84pTysem9ev_HP0Ne0w09_3Rz1s2aZstHCAYau0he3B0Fx4OS_4HEPIN0g |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqIlEuCMpreRqJa7qJ4yT2gUNVqLbQ9NJF6s2yY6cN1carbPbQS_8T_5AZJ0FFAgkJ5WY7iZVxZr6xZ-Yj5INj0lhXmAhskYh4UrNI2lhEOhG5YXAJhye65Vm--Ma_XGQXO-RoyoXBsMpR9w86PWjrsWU-fs35umnm50maC3CvAECEOungAt1DNIBxXQe3d-I8kmxIFc5FhMOnyqMhyAuz4H0b6kPfgLPI2AG6SKig_2yl_oZCgzU6fkQejjCSHg4zfUx2XLtP9j5h6A-yt-2T--V4aP6E_DiknVvp7hqzpOiUCgltITrW0d7TBrNEoO_KVddr37Q9bdqrxjRIxUN9Tcvzk2hBsbQxvey0dbTcVt4huWy38o2lFTIStX6lcTBASrrWne-hIzCEUNzspVPoIl25XgMm3bgNvCWM1sb6QC4GD0Iui6dkefx5ebSIRqaGqEpF3EdMZrVJKoAbecozyR0WedeyynTKdcFrazkYY4AW0hS1NCKpZGItIKO6LsCjS5-R3da37gWhCau4saJG7hzu4lTkjlXOZLF1cc0LNiPpJBi1HupxqClQ7bu6K06F4lSDOGfk4yRD9dvqUmA4_un-95PgFfx-eKaiW-e3G4VOPfqxMpuR58OK-DWvNMdqbFK-_M-3vyN7i2V5qk5Pzr6-Ig-Q8H7YBHpNdvtu694ALOrN27DsfwKC2w6n |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+remarkable+clinical+response+to+immune+checkpoint+inhibitors+of+MSI-H+high+grade+Mucoepidermoid+carcinoma+of+the+parotid+gland+with+multiple+metastases+in+the+abdominal+cavity&rft.jtitle=Oral+oncology&rft.au=Pan%2C+Yanling&rft.au=Li%2C+Yijie&rft.au=Yuan%2C+Feng&rft.au=Lin%2C+Zhiren&rft.date=2023-01-01&rft.eissn=1879-0593&rft.volume=136&rft.spage=106190&rft_id=info:doi/10.1016%2Fj.oraloncology.2022.106190&rft_id=info%3Apmid%2F36463699&rft.externalDocID=36463699 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1368-8375&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1368-8375&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1368-8375&client=summon |